Trinity Partners Unveils Findings Of Its Inaugural Drug Index

BOSTON--(BUSINESS WIRE)--Trinity Partners, a global life sciences consulting firm, announced today the findings of its first annual ‘Trinity Drug Index,’ a comprehensive research-based report which assessed 22 novel drugs approved by the FDA in 2013. The Index rates drug performance as measured by a retrospective look at commercial success relative to therapeutic value and R&D complexity, assigning each drug a score in those three areas as well as an overall composite score.

“It is clear that in today’s market a comprehensive understanding of risks and stakeholder interests is critical to achieving commercial success”

Top findings of this year’s Trinity Drug Index include:

• Sovaldi, which treats Hepatitis C, received the highest ranking with an overall score of 4.4 out of 5
• Most of the top performers were specialty drugs
• Drugs for primary care markets such as COPD and diabetes tend to show weaker differentiation and limited commercial performance, exacerbated by significant R&D expense
• Commercial underperformance given significant therapeutic value is rare, and could be due to a rapidly changing competitive environment
• Well-executed business strategy may boost commercial performance of drugs that are not vastly superior therapeutically
• Moving forward, it will be more critical than ever to demonstrate a product’s value vis-à-vis existing competition

“While ideally therapeutic excellence would always translate to commercial success, in reality that is not always the case,” said John Corcoran, Founder and President, Trinity Partners. “Overall our findings reinforce the idea that the healthcare market is rewarding what is truly valuable for patients; however, the examples of under/overperformance remind us that other factors such as a well-executed business strategy and market differentiation should not be overlooked and play a large role in commercial performance.”

Select case studies are included within the Index to provide additional context of how products overachieve or underperform commercially relative to their perceived therapeutic value. These include a closer look at Pomalyst (overachiever), Kynamro (underperformer) and Osphena (underperformer).

“It is clear that in today’s market a comprehensive understanding of risks and stakeholder interests is critical to achieving commercial success,” said Neal Dunn, Partner, Trinity Partners. “One approach to better understand those factors in order to learn and best plan for the future is to look back at the performance of recently approved drugs to identify what has distinguished those treatments that have profited versus those that haven’t. Our hope is that this analysis will prove helpful to the biopharma community as they look at pipelines for 2017 and beyond.”

To see the full Index click here.

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here: http://www.trinitypartners.com/index.php/our-team/our-partners/.